Merck & Co., Inc. (MRK)

NYQ – Цена в реальном времени. Валюта: USD

128.66

+3.21 (2.56%)

При закрытии: Jun 26, 2026, 4:03 PM EDT

128.20

-0.46 (-0.36%)

После закрытия: Jun 26, 2026, 7:59 PM EDT

17.06.2026

Study Reveals Dog Owners and Veterinarians See Challenges in Treating Allergic Skin Disease, Highlighting a Need for a Targeted Rapid Onset Treatment for Dogs of All Ages

RAHWAY, N.J.--(BUSINESS WIRE)--Merck Animal Health, known as MSD Animal Health outside of the United States and Canada, a division of Merck & Co., Inc., Rahway, N.J., USA (NYSE:MRK), today announced results from a new global survey of dog owners and veterinarians revealing challenges and pain points associated with diagnosing the underlying cause of allergic skin disease in dogs and its treatment. According to Pet Owner and Vet Perspectives on Canine Pruritus: A Global Survey, about one-thi.

16.06.2026

FDA Accepts Gilead's Filing for Weekly Oral Yeztugo for HIV Prevention

Gilead seeks FDA approval for once-weekly oral Yeztugo for HIV prevention, aiming to expand access with a new long-acting PrEP option.

16.06.2026

Protillion Biosciences Announces Drug Discovery Collaboration with Merck

CARLSBAD, Calif.--(BUSINESS WIRE)--Protillion Biosciences, Inc., a leader in lab-in-the-loop AI drug design, today announced the signing of a multi-target discovery collaboration and license agreement with Merck, known as MSD outside the United States and Canada. The agreement combines Protillion's proprietary platform with Merck's global expertise in the discovery of novel therapeutic candidates. “Merck is a global leader in biopharmaceutical innovation, making them an ideal partner to deploy.

16.06.2026

Merck: Buy The Dip On This Dividend Growth Pharma Leader

Merck is a buy-the-dip opportunity after a pullback to $114.90, offering a compelling entry for value and income investors. MRK's robust pipeline, including 20 potential blockbusters and strategic acquisitions like Terns, positions it to bridge the Keytruda patent cliff. Normalized forward P/E of 12.0 and 3% dividend yield support a favorable risk/reward profile.

16.06.2026

3 Dividend Stocks to Hold for the Long Haul

These three healthcare leaders are slowly overcoming recent obstacles. They have strong dividend track records and the means to maintain healthy dividend growth.

12.06.2026

FDA Approves KEYTRUDA® (pembrolizumab) and KEYTRUDA QLEX™ (pembrolizumab and berahyaluronidase alfa-pmph), Each With WELIREG® (belzutifan), for Adjuvant Treatment of Certain Patients With Clear Cell Renal Cell Carcinoma (ccRCC)

RAHWAY, N.J.--(BUSINESS WIRE)---- $MRK #MRK--FDA Approves KEYTRUDA® and KEYTRUDA QLEXTM , Each With WELIREG®, for Adjuvant Treatment of Certain Patients With ccRCC.

12.06.2026

Is It Worth Investing in Merck (MRK) Based on Wall Street's Bullish Views?

The recommendations of Wall Street analysts are often relied on by investors when deciding whether to buy, sell, or hold a stock. Media reports about these brokerage-firm-employed (or sell-side) analysts changing their ratings often affect a stock's price.

Видео

04.02.2026

Positive

CANCER BREAKTHROUGH: Moderna, Merck report cancer discovery

30.01.2026

Positive

5 Stocks That Could Outperform Even in a Pullback

26.01.2026

Negative

Overlooked Stock: RVMD Sells After MRK Turns Away

09.01.2026

Neutral

Trade Tracker: Kevin Simpson buys FedEx, SLB and sells a covered call on Merck

Повышения / Понижения рейтинга

Тикер	Фирма	Изменение рейтинга	Целевая цена	Дата
MRK	Scotiabank	Sector Outperform	undefined >> $105	November 13th 2025
MRK	Citigroup	Neutral	undefined >> $95	October 13th 2025
MRK	Berenberg	Hold	undefined >> $90	September 17th 2025
MRK	Citigroup	Neutral	undefined >> $84	May 14th 2025
MRK	Cantor Fitzgerald	Neutral	undefined >> $85	April 22nd 2025
MRK	Deutsche Bank	Hold	$128 >> $105	February 18th 2025
MRK	TD Cowen	Hold	$121 >> $100	February 10th 2025
MRK	Truist	Hold	undefined >> $110	January 8th 2025

Пресс-релизы

17.06.2026

Study Reveals Dog Owners and Veterinarians See Challenges in Treating Allergic Skin Disease, Highlighting a Need for a Targeted Rapid Onset Treatment for Dogs of All Ages

16.06.2026

Protillion Biosciences Announces Drug Discovery Collaboration with Merck

12.06.2026

FDA Approves KEYTRUDA® (pembrolizumab) and KEYTRUDA QLEX™ (pembrolizumab and berahyaluronidase alfa-pmph), Each With WELIREG® (belzutifan), for Adjuvant Treatment of Certain Patients With Clear Cell Renal Cell Carcinoma (ccRCC)

RAHWAY, N.J.--(BUSINESS WIRE)---- $MRK #MRK--FDA Approves KEYTRUDA® and KEYTRUDA QLEXTM , Each With WELIREG®, for Adjuvant Treatment of Certain Patients With ccRCC.

11.06.2026

Merck Animal Health to Acquire TARGAN

RAHWAY, N.J.--(BUSINESS WIRE)--Merck Animal Health, known as MSD Animal Health outside of the United States and Canada, a division of Merck & Co., Inc., Rahway, N.J., USA (NYSE:MRK), today announced that it has signed a definitive agreement to acquire TARGAN, a privately held innovator in developing and commercializing biodevice solutions to improve performance outcomes for the poultry industry, for an undisclosed purchase price. Merck Animal Health has invested in TARGAN since 2017 and has.

Merck & Co., Inc. (MRK)

Получите доступ ко всем премиум-функциям лучшего инструмента для анализа акций

Finranks

Компания

Контакты

Мы в соцсетях

Merck & Co., Inc. (MRK)

Study Reveals Dog Owners and Veterinarians See Challenges in Treating Allergic Skin Disease, Highlighting a Need for a Targeted Rapid Onset Treatment for Dogs of All Ages

FDA Accepts Gilead's Filing for Weekly Oral Yeztugo for HIV Prevention

Protillion Biosciences Announces Drug Discovery Collaboration with Merck

Merck: Buy The Dip On This Dividend Growth Pharma Leader

3 Dividend Stocks to Hold for the Long Haul

FDA Approves KEYTRUDA® (pembrolizumab) and KEYTRUDA QLEX™ (pembrolizumab and berahyaluronidase alfa-pmph), Each With WELIREG® (belzutifan), for Adjuvant Treatment of Certain Patients With Clear Cell Renal Cell Carcinoma (ccRCC)